Adjuvant Taxotere in Patients With High Risk Prostate Cancer Post Prostatectomy and Radiation

Inclusion Criteria:

* Patients who have undergone a radical prostatectomy (should have unmeasurable PSA) or radiation therapy for prostate cancer and who have high risk disease as defined by one of the following:

  * Node positive disease post-operatively
  * Capsule involvement
  * Seminal Vesicles involvement
  * Gleason score ≥ 8
  * \>50% of core biopsies that are positive
  * Clinical Stage T2c and T3
  * Pre-op PSA \> 15 plus Gleason score of 7

    * Age greater than 18
    * ECOG Performance Status 0-1
    * Serum creatinine \<= 1.5 mg/dl
    * Granulocyte count \>= 1500/m3, Hemoglobin \> 8.0 g/dl, and platelet count \>= 100,000/m3
    * Total bilirubin \<= ULN
    * AST, ALT and Alkaline Phosphatase must be within the range allowing for eligibility.
    * Signed patient informed consent.
    * Men of childbearing potential must be willing to consent to using effective contraception while on treatment and for three months thereafter.

Exclusion Criteria:

* Peripheral neuropathy \> grade 1
* History of severe hypersensitivity to Taxotere® or other drugs formulated with polysorbate 80.
* Patients who have received previous chemotherapy or are being treated on another clinical trial using an investigational agent.
* Active infection within 14 days of beginning treatment
* Patients with a serious illness or medical condition, history of significant neurologic or psychiatric or active infection.
* Patients with a current malignancy. Patients with prior a history of in situ lobular carcinoma of the breast, basal or squamous cell skin cancer, are eligible.